Pricing Log in Create free account

Monte Rosa Therapeutics, Inc. (GLUE) vs Latigo Biotherapeutics Inc (LTGO)

Monte Rosa Therapeutics, Inc. and Latigo Biotherapeutics Inc are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Latigo Biotherapeutics Inc are of similar size ($874.5M and $862.6M). Across the 2 metrics below, Monte Rosa Therapeutics, Inc. leads on 1 and Latigo Biotherapeutics Inc on 1.

Valuation

Metric GLUE LTGO Biotechnology median
P/E n/m — 10.60
P/S 15.18 n/m 9.40
P/B 2.15 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 6.97 n/m 9.02
Earnings yield (13.35%) — (32.88%)
Free cash flow yield (16.33%) 0.00% (23.13%)

Profitability

Metric GLUE LTGO Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin (214.46%) — 0.00%
Net margin (186.24%) — 0.00%
Free cash flow margin (247.98%) — 0.00%
Return on equity (35.30%) — (51.96%)
Return on assets (22.63%) — (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GLUE LTGO Biotechnology median
Revenue growth (TTM) (61.26%) — 6.76%
EPS growth (last fiscal year) 53.06% — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GLUE LTGO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.32 1.15 4.97
Net debt to EBITDA 8.22 — 1.01

Dividend

Metric GLUE LTGO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GLUE LTGO Biotechnology median
Market cap 874.46m 862.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack